股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華控康泰集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01312 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | 本月底法定/註冊股本總額： HK ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 為釐定出席股東特別大會（及現為股東特別大會延會）並於會上投票的股東資格，本 公司暫停辦理股份過戶登記手續的期間維持不變（即二零二五年十月十五日（星期 三）至二零二五年十月二十日（星期一）（包括首尾兩天））。任何於二零二五年十月二 十一日（星期二）至二零二五年十一月七日（星期五）（包括首尾兩天）期間成為股東的 人士將無權出席股東特別大會延會或於會上投票。 除上文所披露者外，該通函、該通告及隨附代表委任表格所載的所有資料及內容均 維持不變。 股東特別大會代表委任表格（「代表委任表格」）已連同該通函及該通告寄發予股東， 就股東特別大會延會而言，其將仍為有效。倘股東已按代表委任表格印列的指示填 妥並交回代表委任表格，相關代表委任表格仍將有效，該股東毋需重新提交代表委 任表格。 – 1 – 倘股東尚未交回代表委任表格但計劃委任代表參加股東特別大會延會，最遲須於股 東特別大會延會舉行時間前四十八小時，向本公司的香港 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華控康泰集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01312 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 – 1 – 本公司董事會（「董事會」）謹此通知本公司股東及潛在投資者，本集團獲全真概念管 理層告知，全真概念的業務狀況正在惡化且已無力償還其尚未償還之債務及負債。 儘管全真概念於過去幾個月已竭盡全力，但其現金流量仍然極度緊張，在台灣健身 行業極具挑戰的業務環境下，其業務狀況仍未能恢復及改善。台灣健身行業在新冠 疫情及經濟不景氣情況下遭受尤其嚴重的打擊。於二零二五年九月三十日，全真概 念公佈全真概念健身中心將自二零二五年十月一日起停止營業，並將遵照台灣相關 法律法規規定評估及於適用情況下採取可能的行動，包括但不限於涉及全真概念歇 業、解散、破產或清算等法律程序。 誠如二零二五年中期業績公告所披露，主要由於台灣健身業務經營困難及財務資源 緊張，本集團確認截至二零二五年六月三十日止期間之減值虧損，包括(i)根據金融 資產（即應收特許權費收入、應收貸款及其他應收款項）預期信貸虧損模式，一間聯 營公司欠款相關之減 ...

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 29 September 2025 Dear Non-registered Shareholder(s) (Note 1) , 華控康泰集團有限公司（「本公司」） Kontafarma China Holdings Limited (the "Company") — Notification of publication of 2025 Interim Report (the "Current Corporate Communication" (Note 2) ) The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.kontafarma.com.hk and the website of The Stock Exchange of Hong ...

Kontafarma China Holdings Limited (the "Company") — Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.kontafarma.com.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corp ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HK$452,723,000, a decrease of 1.7% from HK$458,517,000 in the same period of 2024[11]. - Gross profit for the same period was HK$254,621,000, down 8.1% from HK$277,146,000 year-on-year[11]. - Loss for the period attributable to owners of the company was HK$282,484,000, compared to a profit of HK$4,745,000 in the prior year[12]. - Total comprehensive expense for the period was HK$340,955,000, significantly higher than HK$1,215,000 in the previous year[12]. - Basic loss per share for the period was HK$5.06, compared to earnings of HK$0.09 per share in the prior year[12]. - The company reported a loss for the period of HK$282,484,000 for the six months ended June 30, 2025[17]. - The Group recorded a net loss of approximately HK$321.4 million for the six months ended June 30, 2025, a significant increase from a net loss of approximately HK$4.5 million in 2024[157]. Asset and Equity Changes - As of June 30, 2025, non-current assets decreased to HK$730,458,000 from HK$1,030,423,000 as of December 31, 2024, representing a decline of approximately 29.1%[14]. - Current assets totaled HK$422,582,000, down from HK$557,009,000 at the end of 2024, indicating a decrease of about 24.1%[15]. - Total equity attributable to owners decreased to HK$684,994,000 from HK$978,701,000, reflecting a decline of approximately 30.0%[15]. - Total segment assets as of June 30, 2025, were HK$1,133,923,000, a decrease from HK$1,524,600,000 as of December 31, 2024[44]. Impairment and Losses - Impairment losses recognized under the expected credit loss model amounted to HK$159,035,000, compared to HK$25,466,000 in the same period last year[11]. - Impairment loss on intangible assets increased to HK$123,873,000 in 2025 from HK$13,559,000 in 2024, reflecting a substantial rise[51]. - The Group recognized impairment losses of HK$161,282,000 on amounts due from an associate in 2025, compared to HK$22,565,000 in 2024, indicating a significant increase in credit risk[53]. - The impairment loss on goodwill was recorded at HK$88,417,000, reflecting a significant reduction from the carrying amount of HK$253,418,000 at the beginning of the year[75]. Cash Flow and Financing Activities - Net cash generated from operating activities for the six months ended June 30, 2025, was HK$53,014,000, compared to HK$50,434,000 for the same period in 2024, reflecting an increase of 3.1%[18]. - Net cash used in financing activities totaled HK$46,693,000, slightly down from HK$47,628,000 in the previous year, indicating a decrease of 2.0%[20]. - Cash and cash equivalents at the end of the period increased to HK$78,328,000 from HK$68,663,000, representing a growth of 14.4%[20]. - The Group's bank borrowings stood at HK$82,081,000 as of 30 June 2025, a decrease from HK$85,524,000 as of 31 December 2024[104]. Segment Performance - Pharmaceutical business revenue was HK$344,769,000, slightly down from HK$345,390,000, while fitness business revenue decreased to HK$107,954,000 from HK$113,127,000[37]. - The segment results for the pharmaceutical business showed a profit of HK$20,420,000, down from HK$60,478,000, while the fitness business reported a loss of HK$338,711,000 compared to a loss of HK$38,544,000 in the previous year[37]. - The decline in the fitness business was attributed to slower-than-expected recovery and operational difficulties faced by franchise operators in Taiwan[167]. Marketing and Strategic Initiatives - Increased marketing investment in the pharmaceutical segment led to higher distribution and selling expenses, impacting profitability[163]. - The Group plans to enhance marketing efficiency and intensify product research and development efforts in response to market competition[165]. - The Group's fitness business will strengthen digital marketing efforts to enhance brand image and customer acquisition[197]. - A series of initiatives will be launched, including more diverse membership packages and expanded private training courses, to enhance customer acquisition capabilities[197]. Legal Proceedings and Contingent Liabilities - As of June 30, 2025, the Group has contingent liabilities related to the 2019 Legal Proceedings and 2021 Legal Proceedings, with no material progress made during the interim period[128]. - The Group has been defending claims from Active Gains and Mr. PJW regarding a profit guarantee shortfall for the financial years 2017 and 2018, with 10,000 shares in True Cayman transferred to settle part of the amounts due[129]. - The 2019 Legal Proceedings involve a writ of summons regarding the acquisition of a 51% equity interest in TFKT True Holdings, with no trial date set as of the report date[130]. Employee and Compensation Information - Key management personnel compensation totaled HK$1,884,000 for the six months ended June 30, 2025, compared to HK$2,395,000 in the previous year[112]. - The Group had 655 employees, a decrease from 688 employees as of 31 December 2024[190]. - The share incentive plan aims to motivate selected employees and attract talent for the Group's growth and development[200].

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Shareholder(s) (Note 1) , Kontafarma China Holdings Limited (the "Company") — Notification of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication" (Note 2) ) The English and Chinese versions of the Company's Current Corporate Communications are available on the Compan ...

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholders, Kontafarma China Holdings Limited (the "Company") — Notice of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication") If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 股東特別大會通告 茲通告華控康泰集團有限公司（「本公司」）謹訂於二零二五年十月二十日（星期一）上 午十時正假座香港灣仔謝斐道238號香港諾富特世紀酒店B3層宴會廳3號舉行股東 特別大會（「股東特別大會」）或其任何續會，藉以考慮並酌情通過（無論有否修訂）下 列決議案為本公司之普通決議案。除另有界定者外，本通告所用詞彙與本公司刊發 日期為二零二五年九月二十六日之通函中所定義者具有相同涵義。 普通決議案 「動議 (a) 全面批准、確認及追認本公司之直接全資附屬公司同方藥業集團有限公司（「同 方藥業」）（作為委託人）及北京清控中創工程建設有限公司（「北京清控」）（作為 承包商）所訂立日期為二零二五年八月十八日之建築合約（「北京建築合約」）， 據此同方藥業同意委聘北京清控作為總承包商以進行位於中國北京市延慶區八 達嶺鎮西康路2 3號的研發綜合樓及配套大門的建築工程，合約價為人民幣 33,672,360.58元（可 ...